科學新知
NEW

誰讓舊記憶不被抹去？《Nature》海馬迴協調記憶保存
新聞集錦
NEW

01/15《生技股動態》

生技醫藥
NEW

康霈法說宣布 局部減脂新藥估Q4臨床3期完成收案

生技醫藥
Dupixent 免疫疾病 嗜伊紅性食道炎 EoE Regeneron Sanofi

FDA首批Dupixent治療嗜伊紅性食道炎納入1到11歲幼童  

2024-01-26/記者 吳培安
美國時間25日，再生元(RegeneronPharmaceuticals)與賽諾菲(Sanofi)宣布，其共同開發的免疫疾病藥物Dupixent(dupilumab)獲得美國食品藥物管理局(FDA)再度批准，將嗜伊紅性食道炎(EosinophilicEsophagitis,EoE)的治療對象，新納入1歲到11歲、體重至少15公斤重的兒科患者，成為美國首項批准在此年齡層中，專一性治療EoE的藥物。 ...
生技醫藥
IPO Nasdaq 溶瘤病毒

2024首家IPO生技公司！CG Oncology估值破3.8億美元

2024-01-26/記者 彭梓涵
美國時間25日，開發膀胱癌溶瘤病毒療法的CGOncology宣布在納斯達克(Nasdaq)進行3.8億美元的首次公開募股(IPO)，該公司為今年第一家IPO的生技公司，緊接還有6家生技公司，將為今年IPO拉開序幕。 據了解，CGOncology將以每股19美元價格發行2000萬普通股，扣除佣金其他相關費用，CGOncology將獲得3.8億美元，此金額高過上週設定每股17美元，預計募資1.8億美元...
新聞集錦
新聞集錦

01/26《生醫焦點雷達》

2024-01-26/新聞中心
《人工生殖法》修法箭在弦上代理孕母是否納入引爭議Now健康2024/1/23台新藥眼科止痛藥前進拉丁美洲與巴西簽獨家授權合約經濟日報2024/1/25葡萄王擴展代工「虛擬業務」經濟日報2024/1/25北醫大聯手貝殼生技簽署技轉協議助阻塞型睡眠呼吸中止症患者改善睡眠品質工商時報2024/1/25基因治療藥品調劑里程碑台大醫院基因治療調劑室揭牌Now健康2024/1/25失聰男童終於聽見爸爸聲音，美...
GBI International
GBIHighlights Patent Genomics

Personal Genomics secures victory in the patent battle

2024-01-25/GlobalBio & Investment
ExcitingNews!CongratulationstoPersonalGenomicsforsecuringvictoryinthepatentbattle!TheU.S.AppealsCourtdismissedPacificBiosciences'appealonJanuary9,upholdingtheoriginaldecisionbytheU.S.PatentTrialan...
GBI International
GBIHighlights Healthcare MedicalTech

Globalbio magazine volume 112

2024-01-25/GlobalBio & Investment
Involume112,Globalbiomagazinedivesintothenutsandboltsofimplementinginnovativemedicaltech. Breakingthroughthebarriersfromresearchtoclinicaltrialsisjustthestart,buttherealchallengekicksinaftervalidation...
GBI International
GBIHighlights DigitalPathology TFDA

TFDA certified Jellox Biotech's 'MetaLite DX Digital Pathology Software' as SaMD

2024-01-25/GlobalBio & Investment
BigkudostoJelloxBiotechforreachingasignificantregulatorymilestone!TFDAcertifiedtheir'MetaLiteDXDigitalPathologySoftware'as#SaMD(SoftwareasMedicalDevice)thismonth,markingitthefirstofflineusable...
GBI International
GBIHighlights ADCs Healthcare

The latest progress of ADC drug development in Taiwan

2024-01-25/GlobalBio & Investment
Antibody-drugconjugates(ADCs)featurespecificityandpotentchemotherapy.Sincetheirbreakthroughintreatingsolidtumorsin2019,ADCshavebecomeahotspotforstrategicalliancesandacquisitionsamongpharmaceuticalcomp...
GBI International
GBIHighlights CAR-T Healthcare Biotech celltherapy

The latest progress of six Taiwanese CAR-T therapy developers

2024-01-25/GlobalBio & Investment
GlobalCAR-Tdevelopmentisbustling!AlthoughTaiwanenteredtheCAR-Tfieldlateandfacedhurdleslikepatents,severalcompaniesaretargetingCAR-Tandtakingchallengestomeettheunmetneeds.Theirclinicaltrialsareexpected...
GBI International
GBIHighlights Diabetes TFDA IVD HealthTech

Bio Preventive Medicine Corp.'s DNlite-IVD103 granted TFDA approval

2024-01-25/GlobalBio & Investment
"Bettersafethansorry."CongratulationstoBioPreventiveMedicineCorp.fortheirinnovativekidneydiseasetestkit,DNlite-IVD103,grantedTFDAapproval!Thisbreakthroughbenefitsdiabeticpatientsbypredicting...
GBI International
GBIHighlights Biotech COVID19 Vaccine BIOInsights MVC 蘇益仁

Prof. Ih-Jen Su on Taiwan's biotech industry through the lens of the MVC COVID-19 Vaccine incident

2024-01-25/GlobalBio & Investment
WhatKOLssay:Prof.Ih-JenSuonTaiwan'sbiotechindustrythroughthelensoftheMVCCOVID-19Vaccineincident. ThedevelopmentofCOVID-19vaccineshaspresentedarobustcompetitionmodelforthebiotechindustry.Onlycompan...
GBI International
GBIHighlights

VYSIONEER Collaborates with MC Medical to Introduce the First-ever Brain Tumor Auto Contouring AI

2024-01-25/GlobalBio & Investment
Vysioneer,aleadinginnovatorinOncologyAI,isproudtoannounceastrategiccollaborationwithMCMedical,asubsidiaryofMitsubishiCorporationandawhollyownedsubsidiaryofMCHealthcareHoldingsforbringingadvancedmedica...
GBI International
GBIHighlights

Rockwell Automation is now venturing into Taiwan's biotech industry

2024-01-25/GlobalBio & Investment
EmbracingthefutureofSmartManufacturing(SM),globalindustrialautomationleaderRockwellAutomationisexpandingitsfocustoincludeTaiwan'sbiotechindustry.RecognizingthepivotalroleofTaiwan'sbiopharmaceu...

TOP
  • Global Bio and Investment Monthly
  • 讀者服務電話：+886 2 2726 1065時間：週一 ~ 週五 09:00 ~ 18:00
  • 服務信箱：[email protected]
  • 地址：110臺北市信義區信義路六段29號2樓之一, Taiwan

我們的服務